<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929342</url>
  </required_header>
  <id_info>
    <org_study_id>P15-02 / Pitolisant</org_study_id>
    <secondary_id>2016-000748-32</secondary_id>
    <nct_id>NCT02929342</nct_id>
  </id_info>
  <brief_title>Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers</brief_title>
  <official_title>An Open Label, Single-Period Repeated Dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pitolisant, at Steady-State Conditions, in Healthy CYP2D6 Genotyped Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better define the absorption and elimination pathways, and
      circulating metabolites of Pitolisant at steady state using Pitolisant radiolabelled, in
      healthy CYP2D6 genotyped male subject.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity (Ae) in urine, faeces and expired air.</measure>
    <time_frame>from Day 8 (pre-dose) to 120 h post 14C-radioactivity dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve [AUC(0-tau), AUC(0-inf), %AUCextrap], pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (Clss/F), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The slope of the apparent elimination phase (lambda-z), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The apparent elimination half-life (TÂ½), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (Tmax), pitolisant and major metabolites.</measure>
    <time_frame>From Day 1 (pre-dose) until 168hours post last dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Pitolisant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pitolisant, oral single dose administration, from Day1 to Day7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[14C]-Pitolisant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-Pitolisant, oral single dose administration at Day8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitolisant</intervention_name>
    <arm_group_label>Pitolisant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[14C]-Pitolisant</intervention_name>
    <arm_group_label>[14C]-Pitolisant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged 30 to 65 years.

          -  Body mass index 18.0 to 35.0 kg/m2.

          -  Genotyped with regard to their CYP2D6 status.

        Exclusion Criteria:

          -  Participation in a clinical research study within the previous 3 months

          -  Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study.

          -  Regular alcohol consumption in males &gt;21 units per week.

          -  Current smokers and those who have smoked within the last 12 months.

          -  Evidence of renal impairment at screening, as indicated by an estimated creatinine
             clearance (CLcr) of &lt;90 mL/min using the Cockcroft-Gault equation.

          -  Use of CYP2D6 inhibitors or inducers in the 28 days prior to IMP administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Litza McKenzie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thierry Duvauchelle, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet Pharma</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

